ArticleAsian Pacific journal of cancer prevention : APJCP2026
Exploring the Role Of CD155 in Urothelial Carcinoma of the Urinary Bladder: An Immunohistochemical Study & Its Correlation With PD-L1.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary bladder carcinoma is one of the most immunogenic cancers. Several immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1) have been approved by the FDA for bladder carcinoma treatment. However, additional immunotherapeutic targets are still needed. CD155 is another immune checkpoint molecule that has been shown to be overexpressed in several cancers and is associated with poor prognosis.
aimThis study aimed to evaluate CD155 expression in cases of urinary bladder urothelial carcinoma using immunohistochemistry and to correlate this expression with the clinicopathological parameters of the cases as well as with PD-L1 expression.
methodsImmunohistochemical staining for CD155 and PD-L1 was performed on 67 cases of urothelial carcinoma of the urinary bladder.
resultsCD155 was positive in 41.8% of cases and was significantly associated with invasive tumors and advanced T stage. PD-L1 was positive in 35.8% of cases and was significantly associated with advanced T stage, distant metastasis, muscle invasion and lymphovascular emboli. A statistically significant positive correlation was observed between the expression of both CD155 and PD-L1.
conclusionOur study demonstrated increased expression of CD155 in urothelial carcinoma of the urinary bladder with advancing stage, suggesting its potential as a therapeutic target. Additionally, CD155 expression correlated positively with PD-L1 expression, indicating that some patients might benefit from a combined blockade of both targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.